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This review was derived from a presentation made on 
September 2, 2016, for the first Academy Day presented by the 
Working Party on Immunohematology at the International 
Society of Blood Transfusion (ISBT) Congress in Dubai. The focus 
of this review is on the clinical significance of alloimmunization 
in transfusion—specifically, the parameters that contribute to 
a clinically significant alloantibody. The areas of focus were as 
follows: Introduction, Technical Aspects, and Indications and 
Limitations. Each section contains a brief review of selected 
literature and experiential knowledge. Case reports are needed 
to collect data on current outcomes of incompatible transfusion. 
The ISBT Working Party on Rare Donors has developed a form 
to capture case-specific information. Immunohematology 
2018;34:11–15.
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Introduction
When transfusion was first implemented, little was 
known about the alloantibodies produced as a side effect of the 
procedure. Dr. Philip Syng Physick from Philadelphia is given 
credit for the first human blood transfusion in 1795. Although 
Dr. Physick did not publish the event, Dr. De Wees credits him 
with the transfusion in a comment in a journal article in 1825 
for the event 30 years earlier.1 In 1818, British obstetrician 
James Blundell performed the first successful transfusion 
of human blood (4 mL) to a patient for the treatment of 
postpartum hemorrhage.2
From these early times emerged the discipline of transfu-
sion medicine and, within this discipline, immunohematology. 
The study of the immune response to transfusion has 
become an integral part of the treatment of patients. Fewer 
than 10 percent of first-time transfusion recipients make 
alloantibodies, compared with reported percentages of up to 
40 percent in multiply transfused patients. Only a fraction 
of patients will form antibodies to the foreign red blood 
cells (RBCs) they receive which subsequently may destroy a 
fraction of or all of the foreign RBCs; this possibility negates 
the positive effects of transfusion. Thus, alloimmunization is 
considered a significant side effect. Only for certain categories 
of patients in selected centers is it common practice to match 
the antigens of the patient and of the blood for transfusion 
before antibodies are made It is remarkable that this significant 
side effect of transfusion has not resulted in a uniform goal of 
phenomatching or genomatching all patients receiving RBC 
transfusions.
Defining the clinical significance of RBC alloantibodies has 
been pursued for many years, and today we still do not know 
how to predict the outcome of transfusion for an individual 
patient. Organizations have developed their own definitions; 
the one that is most suitable is that of the British Committee 
for Standards in Haematology Blood Transfusion Task Force3: 
Clinically significant antibodies are those that are capable of 
causing patient morbidity due to accelerated destruction of a 
significant portion of transfused RBCs. Other groups, like the 
AABB, have defined a clinically significant antibody as “an 
antibody that is frequently associated with hemolytic disease 
of the fetus and newborn, hemolytic transfusion reaction, or 
a notable decrease in survival of transfused red cells.”4 The 
pathogenic activity of RBC alloantibodies varies from that 
of no clinical evidence of RBC destruction to destruction of 
transfused allogeneic RBCs in an acute or delayed hemolytic 
transfusion reaction (DHTR). There is also an alloimmune 
response that results in serologic evidence of new alloantibody 
formation or detection of antibody bound to transfused RBCs 
(positive direct antiglobulin test) but no clinical evidence of 
destruction of transfused RBCs. This event has been termed 
a delayed serologic transfusion reaction (DSTR). Other 
pathogenic evidence is seen in the destruction of fetal or 
newborn RBCs by maternal alloantibodies (termed hemolytic 
disease of the fetus and newborn [HDFN]) and in transplants 
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(destruction of transplanted tissue [transplant rejection] and 
destruction of cells of the recipient by donor immune cells in 
graft-versus-host disease). The phenomenon of destruction 
of not only the transfused RBCs but also of the patient’s 
autologous RBCs in a hyperhemolysis event has also been 
described but will not be covered here.
The U.S. Food and Drug Administration Department 
of Regulation compiles and releases annual statistics on 
death associated with transfusion. In the most recent data 
posted from 2014, tracked information included deaths due 
to hemolytic transfusion reaction (HTR) from ABO and 
non-ABO antibodies. In 2014, there were eight fatalities 
attributed to HTRs—down from a high of over 25 reported 
in 2002; four of these deaths were caused by ABO antibodies 
and four were caused by non-ABO antibodies. The non-
ABO antibodies associated with the deaths in 2014 included 
one newly identified anti-C, one anti-Jka, and two ascribed 
to a category of “other.” The anti-C was identified in a post-
transfusion sample, and the anti-Jka death was due to a 
mislabeled unit. One case classified as “other” was of a warm-
reactive autoantibody with concomitant anti-Jka and anti-Fya 
and a new anti-M (determined to not be implicated) with no 
other newly identified alloantibodies. The final reported case 
was a patient with sickle cell disease with multiple preexisting 
known antibodies who developed hyperhemolysis with no 
additional alloantibodies detected.5
In the UK, the Serious Hazards of Transfusion (SHOT) 
hemovigilance data are tracked in three categories: transfusion 
reactions that may not be preventable, transfusion reactions 
that are possibly or probably preventable with improved 
practice and monitoring, and adverse events caused by errors.6 
In these three categories, from 1996 to 2013, there were over 
2500 reports in the first category, over 500 in the second, and 
over 1500 in the last category attributed to D/anti-D errors. 
For the years 1996–2013, there were 13,141 total adverse 
transfusion events reported, with anti-D alloimmunization 
being approximately 1500 cases, with 500 HTRs. In looking 
at hemovigilance data from France from 2008 to 2013, there 
were 11,625 reports of alloimmunization, with 3617 occurring 
in patients aged older than 80 years, and the highest rate was 
found in patients aged 55–79 years.7
Technical Aspects
The technical aspects regarding the determination of the 
significance of RBC alloantibodies are based on experiential 
information, what textbooks report, and selected research 
studies.
Of foremost importance in considering the significance 
of a RBC alloantibody is determining whether the antibody 
is reactive solely at room temperature or body temperature 
(37°C). It is most generally practiced that if an alloantibody is 
not reactive at body temperature, then the specificity does not 
need to be considered in the selection of blood for transfusion. 
If the antibody is reactive at body temperature, however, then, 
in the absence of other studies showing or predicting the 
antibody to be clinically insignificant, one should transfuse 
antigen-negative blood.
Standard practice is to select blood for transfusion that 
is negative for the antigen, if the antibody is to a common 
antigen that has been known to be associated with transfusion 
reactions (e.g., anti-C, anti-K, anti-Jka). See Table 1 for 
predictions of clinical significance of antibodies based on 
specificity. The literature is not absolute on clinical significance 
of all antibodies detected with methods used more than 20 
years ago.8–10 The literature is also not strong on antibody 
specificity and clinical significance using methods currently 
used in transfusion services for antibody detection, that is, 
automated methods (that were not in use at the time of the 
reports on specific antibody clinical significance). There is a 
global initiative to collect the literature that is known in this 
area and have it available in an electronic online database 
called the Notify Library.11
Consideration for selection and identification of antibody 
techniques should be given to determining whether an 
antibody is IgM or IgG when there is risk to a fetus or 
newborn through the presence of a maternal antibody. If an 
IgM antibody is present, there is no risk to the fetus because 
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Table 1. Predictions of clinical significance by antibody specificity
Usually clinically significant:
ABO, D, C, c, E, e, K, k, Fya, Fyb, Jka, Jkb, S, s, U, Doa, Dob, Vel
Clinical significance variable by patient:
Yta, Ge, Gya, Hy
Clinically significant if reactive at 37°C:
Lea, Leb, M, N, P1, Lua, Lub, A1
Usually clinically insignificant:
Cha, Rga, Xga, Bg, Csa, Kna, McCa, Yka, JMH, Sda*, “HTLA-like”
Agreement does not exist in the literature for all antigens in all categories, 
and this list is not inclusive of all alloantibodies to blood group antigens.
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IgM antibodies do not cross the placenta. IgG antibodies do 
cross the placenta, however, and it is important to monitor 
these antibodies in the pregnant mother, particularly anti-D. 
From a transfusion perspective, if an IgM antibody is reactive 
in strict prewarmed testing at 37°C by agglutination, then 
the transfusionist should use blood selected and tested to be 
negative for the antigen. IgM antibodies seldom react at 37°C, 
but, when they do, they can be detected by agglutination at 
37°C or at the antihuman globulin (AHG) phase by the anti-C3 
component of polyspecific AHG reagent if complement has 
been activated. IgG antibodies are seldom detected at 37°C 
by agglutination because, although IgG antibodies commonly 
sensitize reagent RBCs at 37°C, this sensitization cannot be 
visualized by macroscopic examination at that temperature, 
but only visualized at the AHG phase through the binding of 
anti-IgG. Antibodies to common antigens reactive at 37°C and 
detected in the AHG phase are important to consider in the 
selection of blood.
Indications and Limitations
Although Table 1 lists commonly encountered specificities 
and groups them into categories of clinical significance, it is 
important to recognize that these categories are not always 
going to be correct for 100 percent of the antibody specificities 
identified. It is especially important to publish and register the 
outcomes of incompatible transfusions in the Notify Library 
because detection methods have changed since the early 
publications on the outcome of incompatible transfusions 
for commonly encountered antibodies. Additionally, there is 
literature to support the idea that not all antibodies have the 
same destruction potential. For example, Garratty12 noted 
that, of 559 patients studied, there were common antibodies 
that were reported to cause a DHTR with clinical signs of 
transfused RBC destruction. As an example, in 95 patients 
with anti-Jka, 45 patients (47%) were reported to have a 
DHTR and 50 (53%) a DSTR. Thus, although a significant 
percentage of the patients with anti-Jka demonstrated 
positive serologic reactions (DSTR), no clinical signs of RBC 
destruction were seen in these patients. Table 2 shows more 
of the data reported. Of interest, for the antibodies shown in 
Table 2, some specificities (e.g., anti-E, -Jka, -K, -Fyb, and -Jkb) 
have been associated with transfusion reactions. In total, in 65 
percent of these cases, DSTR was the outcome reported rather 
than HTR or DHTR. Thirty-five percent of these antibody 
specificities did cause DHTR, however, so these specificities 
should be considered clinically relevant for transfusion, with 
the recognition (again) that not all patients will have the same 
outcome. It is important to consider all possible outcomes in 
making decisions for transfusion. A test with a 100 percent 
positive predictive value to predict the outcome for each patient 
transfused would be highly useful. It would also be helpful to 
know which patients will form antibodies.
The strength of reactivity and degree of destruction of 
transfused-incompatible RBCs have not been well studied 
for their relevance to transfusion outcomes, but in this 
author’s experience, when there is an antibody that cannot be 
identified, or an antibody to an antigen of high prevalence, a 
4+ reactive antibody is regarded more seriously than one that 
is less than 1+. However, the outcomes of transfusion have not 
been correlated with a measurement of strength of reactivity. 
The method used can influence the strength of reactivity, 
since different methods have different sensitivity levels. 
Experience shows that not all antibodies that are weakly 
reactive are clinically insignificant, nor are all strongly reactive 
antibodies clinically significant. Zupanska et al.13 studied the 
in vitro phagocytosis of RBCs with known amounts of RBC-
bound IgG, with the outcome that there was a relationship to 
monocyte phagocytosis and the number of RBC-bound IgG 
molecules, although there was variation between individuals. 
The correlation between in vivo hemolysis and the amount of 
RBC-bound IgG has also been studied by flow cytometry.14,15
The IgG subclasses of IgG alloantibodies have been 
studied for their association with clinical outcomes. It 
is known that IgG1, IgG2, and IgG3 subclasses activate 
complement and interact with macrophage Fc receptors. It is 
thought that antibodies of the IgG4 subclass should not cause 
RBC destruction because they do not activate complement or 
interact with macrophage Fc receptors. Nevertheless, because 
most antibodies are IgG1 with or without other subclasses, it 
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Table 2. DHTR versus DSTR for some commonly encountered 
antibody specificities
Antibody 
specificity Total N DHTR (n) DSTR (n) % DSTR
E 184 47 137 74
Jka 95 45 50 53
Fya 62 26 36 58
K 62 16 46 74
Fyb 12 4 8 67
Jkb 17 3 14 82
Total 559 197 362 65
Adapted from Garratty.12 DHTR = delayed hemolytic transfusion reaction; 
DSTR = delayed serologic transfusion reaction.
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is difficult to use IgG subclass information for the prediction 
of the clinical significance of RBC alloantibodies. It has 
been reported that some antibodies may not be able to be 
subclassed by a standardized capillary test, possibly because 
reactions with antisera to IgG subclasses are weaker than with 
anti-IgG.14 Zupanska et al.13 reported that there was a higher 
degree of phagocytosis with fewer IgG3 molecules than with 
IgG1 molecules. That report also contained interesting still 
photographs of phagocytosis taken from a videotape of the 
testing as it progressed. The commentary that accompanied 
the photographs reported that the RBCs with bound IgG 
adhered to the monocytes for a considerable length of time 
before phagocytosis, but that once phagocytosis began, 
consumption of the RBCs was rapid.
In vitro tests have been reported that seek to predict the 
clinical significance of an antibody present in a patient who is 
pregnant or who needs transfusion. For pregnant patients with 
IgG antibodies, it is often desired to perform noninvasive tests 
to seek information rather than turn immediately to invasive 
tests. Often, titers are requested to provide an indication of 
the strength of the reactivity. Only anti-D has been studied 
effectively in an attempt to use a titer result to decide on invasive 
procedures; other antibody specificities are less well studied, 
and a titer endpoint has not been correlated to pregnancy 
outcome. Antibody-dependent cell-mediated cytotoxicity 
(ADCC) and chemiluminescence assays have been reported to 
be best for predicting HDFN. The ADCC assay detects RBC 
lysis by quantitating the released 51Cr by a gamma counter. 
One limitation to this method is that antibodies to enzyme-
sensitive antigens cannot be studied because enzyme-treated 
RBCs are used in the test.16,17 Chemiluminescence reports 
results based on released oxygen radicals that cause luminol 
to emit light
For patients who need transfusion, the monocyte 
monolayer assay (MMA) has been used to predict the clinical 
significance of antibodies.18–21 Commonly, the MMA is used in 
the United States when no blood of the requested blood type 
can be found domestically before making an international 
request. A negative MMA indicates that random RBCs 
(untyped for the indicated antigen) can be transfused for the 
immediate transfusion event. If more transfusions are needed 
later, the MMA must be performed with a current sample as 
close to the time of transfusion in the event that the antibody’s 
characteristics have changed. Historically, but not often used 
today, are the in vivo tests: the 51Cr red cell survival study 
described by Mollison22 and the in vitro measure of in vivo 
survival by differential agglutination and flow cytometry,23 
both of which require the transfusion of incompatible blood 
and then the measurement of the survival of the transfused 
aliquot.
Clearly, more data would be useful in making transfusion 
decisions when antigen-negative blood is not readily available. 
The previously mentioned Notify Library will collect peer-
reviewed publications on transfusion outcomes involving 
blood group specificities. Additionally, the ISBT Working 
Party on Rare Donors recently launched a form, Outcome of 
Incompatible Transfusion: Case Study Report (Fig. 1), on the 
ISBT Web site to track outcomes of incompatible transfusions.24 
This form is intended for use when a patient has an antibody 
identified and an incompatible transfusion is given deliberately 
or by mistake. The purpose is to track the outcome by antibody 
specificity to provide information to clinicians who must make 
a transfusion decision when blood is needed and not available.
Fig. 1 International Society of Blood Transfusion Working Party 
on Rare Donors form: Outcome of Incompatible Transfusion: Case 
Study Report. Reprinted from Nance et al.24
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Evaluations from the Academy Day showed that the 
attendees appreciated the concentrated review and the 
discussions about the clinical significance of alloantibodies.
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